The importance of the CD4:CD8 ratio in the T cell infusions for patients receiving immunotherapy for cancer treatment has been highlighted by several previous reports, with a ratio of 1:1 commonly proposed to drive optimal clinical responses [52,53]. This evidence concerns the gene CD8A and cancer.